In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis
- 4 August 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 38 (11), 2066-2076
- https://doi.org/10.1007/s00259-011-1886-x
Abstract
Angiogenesis is an indispensable process during tumor development. The currently accepted standard method for quantifying tumor angiogenesis is to assess microvessel density (MVD) based on CD105 staining, which is an independent prognostic factor for survival in patients with most solid tumor types. The goal of this study is to evaluate tumor angiogenesis in a mouse model by near-infrared fluorescence (NIRF) imaging of CD105 expression.Keywords
This publication has 40 references indexed in Scilit:
- Positron emission tomography imaging of CD105 expression during tumor angiogenesisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Tumor Angiogenic Marker Expression Levels during Tumor Growth: Longitudinal Assessment with Molecularly Targeted Microbubbles and US ImagingRadiology, 2011
- Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumoursCardiovascular Research, 2009
- Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for TherapyClinical Cancer Research, 2008
- Are quantum dots ready for in vivo imaging in human subjects?Nanoscale Research Letters, 2007
- Near-Infrared Fluorescence Imaging of Tumor Integrin αvβ3 Expression with Cy7-Labeled RGD MultimersMolecular Imaging & Biology, 2006
- Angiogenesis in life, disease and medicineNature, 2005
- Perfusion of99Tcm-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular targetInternational Journal of Cancer, 2004
- Molecular imaging in living subjects: seeing fundamental biological processes in a new lightGenes & Development, 2003
- Imaging of tumour neovasculature by targeting the TGF-β binding receptor endoglinEuropean Journal of Cancer, 2000